Bioequivalence study of ibuprofen extended-release 800 mg tablets

Bioequivalence study of 800 mg slow-release ibuprofen tablets from Farnoush Darou Teb Company compared to 800 mg slow-release ibuprofen from Abbott Company, Turkey, on healthy volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230222057495N25

Enrollment

Registered

2025-08-10

Start date

2025-08-09

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention group 1: Includes oral administration of 800 mg ibuprofen slow-release tablets from Farnoush Darou Teb Company, Iran, on 24 healthy volunteers on an empty stomach. 5 ml of blood is taken

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Healthy volunteer between 18 and 55 years old. Body mass index less than 30 kg per square meter. All candidates must be non-smokers.

Exclusion criteria

Exclusion criteria: Blood pressure less than 90 on 60 mm Hg or more than 140 on 90 mm Hg. Consumption of any drug, alcohol or tobacco within 2 weeks before receiving the drug.

Design outcomes

Primary

Measure	Time frame
Maximum plasma concentration of ibuprofen. Timepoint: Before taking the drug and: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 24 hours after taking the drug. Method of measurement: Liquid chromatography-mass spectrometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Jalalipour

Nik Azma Pars Alborz Laboratory

info@naplab.ir+98 26 3612 2350

Outcome results